These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31464781)

  • 1. Bile acids and butyrate in the effects of probiotics/synbiotics on nonalcoholic fatty liver disease.
    Chen J; Vitetta L
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1475-1476. PubMed ID: 31464781
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients.
    Buss C; Valle-Tovo C; Miozzo S; Alves de Mattos A
    Ann Hepatol; 2014; 13(5):482-8. PubMed ID: 25152979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models.
    Jena PK; Sheng L; Nagar N; Wu C; Barile D; Mills DA; Wan YY
    J Nutr Biochem; 2018 Jul; 57():246-254. PubMed ID: 29800811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis.
    Vakhrushev YM; Lukashevich АР; Penkina IA; Suchkova EV
    Ter Arkh; 2019 Mar; 91(2):48-51. PubMed ID: 31094171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach.
    Sangouni AA; Ghavamzadeh S
    Diabetes Metab Syndr; 2019; 13(5):2917-2922. PubMed ID: 31425956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids and nonalcoholic fatty liver disease: An intriguing relationship.
    Carulli L; Gabbi C; Bertolotti M
    Hepatology; 2016 May; 63(5):1739-40. PubMed ID: 26122405
    [No Abstract]   [Full Text] [Related]  

  • 10. Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions.
    Geirnaert A; Steyaert A; Eeckhaut V; Debruyne B; Arends JB; Van Immerseel F; Boon N; Van de Wiele T
    Anaerobe; 2014 Dec; 30():70-4. PubMed ID: 25179909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of probiotics in treatment of nonalcoholic fatty liver disease].
    Chen M; Wang MC; Ni R; Wang J; Wang L; Wang GN; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jan; 25(1):77-80. PubMed ID: 28297790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More evidence that probiotics may have a role in treating fatty liver disease.
    Maddur H; Neuschwander-Tetri BA
    Am J Clin Nutr; 2014 Mar; 99(3):425-6. PubMed ID: 24500146
    [No Abstract]   [Full Text] [Related]  

  • 17. The perspective on cholesterol-lowering mechanisms of probiotics.
    Ishimwe N; Daliri EB; Lee BH; Fang F; Du G
    Mol Nutr Food Res; 2015 Jan; 59(1):94-105. PubMed ID: 25403164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
    Cho YK
    Clin Mol Hepatol; 2018 Sep; 24(3):299-301. PubMed ID: 30196651
    [No Abstract]   [Full Text] [Related]  

  • 19. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.